Yaping Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yaping Ma has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Yuan Zhou
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122 , China
12 shared publicationsFan-Sheng Kong
Department of Paediatrics, Affiliated Hospital of Jiangnan University, Wuxi, 214122, Jiangsu, China
9 shared publicationsPanwang Huang
Department of Paediatrics, Affiliated Hospital of Jiangnan University, Wuxi, 214122, Jiangsu, China
9 shared publicationsRuofan Jia
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122 , China
9 shared publications- Zhuangjian Xu
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
8 shared publications Beilei Zeng
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122 , China
6 shared publications
Latest Publications
- 19 June 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (9) , 1804-1815
A Risk Score for Polycystic Ovary Syndrome Based on Meta-Analysis and Machine Learning of Gut Microbiota Signatures
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine and metabolic disorder among reproductive-age women, in which emerging evidence suggests a substantial role played by the gut microbiota. To comprehensively evaluate gut microbiota alterations in PCOS and identify microbial biomarkers through integrated analysis, a systematic search of PubMed, Web of Science, and Embase was conducted for studies employing 16S rRNA gene sequencing of fecal samples from PCOS cohorts. Ten eligible PCOS cohorts, comprising 858 individuals, were included in the study, from which a risk score was derived using a 20-gene gut microbial signature associated with PCOS. Meta-analysis at the genus level identified that Subdoligranulum, NK4A214_group, and Collinsella significantly decreased, and Bacteroides increased in PCOS across multiple cohorts. Machine learning analysis identified a 20-genus microbial signature using the least absolute shrinkage and selection operator (LASSO) method, which was used to construct a risk score with an AUC of 0.835 in diagnosis prediction. Network analysis further identified Negativibacillus and Lachnospiraceae_UCG_010 as potential driver microbes in PCOS. The analysis in this study highlights key alterations in the gut microbiota across PCOS cohorts. The identified gut microbial signature and derived LASSO-based risk model offer novel insights and a potential tool for PCOS diagnosis.
- 19 June 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (9) , 1804-1815
A Risk Score for Polycystic Ovary Syndrome Based on Meta-Analysis and Machine Learning of Gut Microbiota Signatures
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine and metabolic disorder among reproductive-age women, in which emerging evidence suggests a substantial role played by the gut microbiota. To comprehensively evaluate gut microbiota alterations in PCOS and identify microbial biomarkers through integrated analysis, a systematic search of PubMed, Web of Science, and Embase was conducted for studies employing 16S rRNA gene sequencing of fecal samples from PCOS cohorts. Ten eligible PCOS cohorts, comprising 858 individuals, were included in the study, from which a risk score was derived using a 20-gene gut microbial signature associated with PCOS. Meta-analysis at the genus level identified that Subdoligranulum, NK4A214_group, and Collinsella significantly decreased, and Bacteroides increased in PCOS across multiple cohorts. Machine learning analysis identified a 20-genus microbial signature using the least absolute shrinkage and selection operator (LASSO) method, which was used to construct a risk score with an AUC of 0.835 in diagnosis prediction. Network analysis further identified Negativibacillus and Lachnospiraceae_UCG_010 as potential driver microbes in PCOS. The analysis in this study highlights key alterations in the gut microbiota across PCOS cohorts. The identified gut microbial signature and derived LASSO-based risk model offer novel insights and a potential tool for PCOS diagnosis.
- Open Access
- 21 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 830
The value of urinary gonadotropin after triptorelin stimulation tests for diagnosing central precocious puberty in girls with overweight or obesity: a single-center study
Background There are different opinions about the effect of body mass index on gonadotropin-releasing hormone stimulation tests in the laboratory diagnosis of precocious puberty in girls. The blood collection of precocious puberty girls with overweight or obesity is more difficult than those with normal body mass index. It is urgent to find non-invasive diagnostic methods for these girls. The purpose of the study was to evaluate the value of urinary gonadotropin after triptorelin stimulation tests for diagnosing central precocious puberty (CPP) in girls with overweight or obesity. Methods This was a hospital data-based retrospective study. Overweight or obese girls with precocious puberty who presented to our pediatric endocrine clinic were involved. Triptorelin (Decapeptyl, 0.1 mg) stimulation tests were performed at 8:30 am. On the triptorelin test day, urine sample collected from 08:30 am to 8:30 pm was defined as the first stimulated urine. Serum and urinary luteinizing hormone (LH) were measured by immunochemiluminometric assay. Urinary creatinine (Cr) was also measured. Results There were 52 girls with overweight or obesity. They were divided into CPP (n = 36) and peripheral precocious puberty (PPP) (n = 16) groups. The stimulated urinary LH (ULH) concentration corrected by Cr (ULH/Cr), ULH concentration, and ULH content in the CPP group were significantly higher than those in the PPP group. When the first stimulated ULH/Cr, ULH concentration and ULH content were ≥ 239.142 IU/mol, 1.690 IU/L and 619.750 IU, and sensitivity for diagnosing CPP in girls with overweight or obesity were 90.9%, 78.8% and 81.8%, respectively, and specificity were all 100%, and the area under the curve were 0.939, 0.932 and 0.909, respectively. Conclusions For overweight or obese girls with precocious puberty, the first stimulated ULH/Cr (cut-off value 240 IU/mol) may be used as a possible alternative to the invasive blood detection of triptorelin stimulation tests for diagnosing CPP.
- 21 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 830
Open AccessThe value of urinary gonadotropin after triptorelin stimulation tests for diagnosing central precocious puberty in girls with overweight or obesity: a single-center study
Background There are different opinions about the effect of body mass index on gonadotropin-releasing hormone stimulation tests in the laboratory diagnosis of precocious puberty in girls. The blood collection of precocious puberty girls with overweight or obesity is more difficult than those with normal body mass index. It is urgent to find non-invasive diagnostic methods for these girls. The purpose of the study was to evaluate the value of urinary gonadotropin after triptorelin stimulation tests for diagnosing central precocious puberty (CPP) in girls with overweight or obesity. Methods This was a hospital data-based retrospective study. Overweight or obese girls with precocious puberty who presented to our pediatric endocrine clinic were involved. Triptorelin (Decapeptyl, 0.1 mg) stimulation tests were performed at 8:30 am. On the triptorelin test day, urine sample collected from 08:30 am to 8:30 pm was defined as the first stimulated urine. Serum and urinary luteinizing hormone (LH) were measured by immunochemiluminometric assay. Urinary creatinine (Cr) was also measured. Results There were 52 girls with overweight or obesity. They were divided into CPP (n = 36) and peripheral precocious puberty (PPP) (n = 16) groups. The stimulated urinary LH (ULH) concentration corrected by Cr (ULH/Cr), ULH concentration, and ULH content in the CPP group were significantly higher than those in the PPP group. When the first stimulated ULH/Cr, ULH concentration and ULH content were ≥ 239.142 IU/mol, 1.690 IU/L and 619.750 IU, and sensitivity for diagnosing CPP in girls with overweight or obesity were 90.9%, 78.8% and 81.8%, respectively, and specificity were all 100%, and the area under the curve were 0.939, 0.932 and 0.909, respectively. Conclusions For overweight or obese girls with precocious puberty, the first stimulated ULH/Cr (cut-off value 240 IU/mol) may be used as a possible alternative to the invasive blood detection of triptorelin stimulation tests for diagnosing CPP.
- Open Access
- 21 August 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1629423
A single blood luteinizing hormone level of triptorelin stimulation test can diagnose hypothalamic-pituitary-gonadal axis activation in girls with high body mass index
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.Methods: This was a hospital data-based retrospective study. Girls with puberty disorders who had been followed up for six months to two years were enrolled in the study. They were divided into the overweight/obesity group and the normal BMI group and all underwent triptorelin stimulation test. Blood samples were collected at 0 min before and 20, 40, and 60 min after the test. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) serum concentrations were quantified by immunochemiluminometric assay.Results: A total of 422 girls who underwent 454 triptorelin stimulation tests were included in this study. Among 148 tests performed on 142 overweight/obesity girls, 110 tests were hypothalamic-pituitary-gonadal axis (HPGA) activated and 38 tests were HPGA non-activated. Among 306 tests performed on 284 girls with normal BMI, 214 tests were HPGA activated and 92 tests were non-activated. LH, FSH, and estradiol levels in girls whose HPGA activated were significantly higher than those non-activated. The area under the curves of LH20 min, LH40 min, LH60 min and PLH after triptorelin stimulation tests in girls with overweight/obesity for diagnosing HPGA activation were 0.996, 0.980, 0.990 and 0.994, respectively. There was no statistical significance in the area under the curves between LH20 min, LH40 min, LH60 min and PLH. When LH20 min, LH40 min, LH60 min and PLH were ≥3.26 IU/L, ≥4.09 IU/L, ≥4.27 IU/L and ≥4.51 IU/L, the sensitivity for diagnosing HPGA activation in girls with overweight/obesity were 99.03%, 95.45%, 98.18% and 97.27%, and the corresponding specificity were 94.59%, 97.37%, 100.00%, and 100.00%, respectively. The cut-off value of serum LH60 min after the triptorelin stimulation test for diagnosing HPGA activation in precocious pubertal girls with overweight/obesity was 4.45 IU/L, and in pubertal girls with overweight/obesity was 4.20 IU/L.Conclusions: LH measurements obtained at 20, 40, or 60 min post-triptorelin stimulation can diagnose HPGA activation in girls with high BMI.
- 21 August 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1629423
Open AccessA single blood luteinizing hormone level of triptorelin stimulation test can diagnose hypothalamic-pituitary-gonadal axis activation in girls with high body mass index
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.Methods: This was a hospital data-based retrospective study. Girls with puberty disorders who had been followed up for six months to two years were enrolled in the study. They were divided into the overweight/obesity group and the normal BMI group and all underwent triptorelin stimulation test. Blood samples were collected at 0 min before and 20, 40, and 60 min after the test. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) serum concentrations were quantified by immunochemiluminometric assay.Results: A total of 422 girls who underwent 454 triptorelin stimulation tests were included in this study. Among 148 tests performed on 142 overweight/obesity girls, 110 tests were hypothalamic-pituitary-gonadal axis (HPGA) activated and 38 tests were HPGA non-activated. Among 306 tests performed on 284 girls with normal BMI, 214 tests were HPGA activated and 92 tests were non-activated. LH, FSH, and estradiol levels in girls whose HPGA activated were significantly higher than those non-activated. The area under the curves of LH20 min, LH40 min, LH60 min and PLH after triptorelin stimulation tests in girls with overweight/obesity for diagnosing HPGA activation were 0.996, 0.980, 0.990 and 0.994, respectively. There was no statistical significance in the area under the curves between LH20 min, LH40 min, LH60 min and PLH. When LH20 min, LH40 min, LH60 min and PLH were ≥3.26 IU/L, ≥4.09 IU/L, ≥4.27 IU/L and ≥4.51 IU/L, the sensitivity for diagnosing HPGA activation in girls with overweight/obesity were 99.03%, 95.45%, 98.18% and 97.27%, and the corresponding specificity were 94.59%, 97.37%, 100.00%, and 100.00%, respectively. The cut-off value of serum LH60 min after the triptorelin stimulation test for diagnosing HPGA activation in precocious pubertal girls with overweight/obesity was 4.45 IU/L, and in pubertal girls with overweight/obesity was 4.20 IU/L.Conclusions: LH measurements obtained at 20, 40, or 60 min post-triptorelin stimulation can diagnose HPGA activation in girls with high BMI.
- 13 August 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (6) , 395-403
Urinary follicle-stimulating hormone during triptorelin stimulation test can monitor the efficacy of triptorelin depot in girls with precocious or early puberty
- 13 August 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (6) , 395-403
Urinary follicle-stimulating hormone during triptorelin stimulation test can monitor the efficacy of triptorelin depot in girls with precocious or early puberty
- Open Access
- 11 August 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1576434
Cardiovascular abnormalities in children with Turner syndrome: a 15-year retrospective study and analysis of warning signs
Background/Objective: There are limited studies on cardiovascular abnormalities (CAs) and their warning signs in children with Turner syndrome (TS). The main aim of this 15-year retrospective study was to investigate the warning signs of CAs in children with TS and to suggest ways to prevent them.Methods: This retrospective study analyzed children diagnosed with TS at our pediatric endocrinology clinic. The study examined patients with TS with CAs and their warning signs.Results: A total of 37 cases were included in our study. The average age at presentation was 7.48 ± 3.49 years. According to the results of transthoracic echocardiography, the children were divided into two groups: (1) TS without CAs (n = 31) and (2) TS with CAs (n = 6). The incidence rate of CAs was 16.2% (6/37). Of the six cases, five had congenital heart disease, four of which underwent cardiac surgery. One patient developed descending aortic coarctation during growth hormone therapy and underwent aortic coarctation repair surgery. The proportions of haplotypes, chimeric types, and structural abnormalities in the TS without CAs group were 9/31, 16/31, and 6/31, respectively. In the TS with CAs group, these proportions were as follows: 1/6, 3/6, and 2/6, respectively. A comparative analysis revealed no statistically significant variation in karyotype frequencies between the two groups. In the TS without CAs group, 0.0% of the mothers had abnormal blood pressure during pregnancy. In the TS with CAs group, the incidence of hypertension in the mothers during pregnancy was 33.3%. A significant difference in gestational hypertension was observed between the two groups (P = 0.016). However, no significant differences were observed between the groups in terms of heart rate or blood pressure parameters (systolic/diastolic).Conclusions: Children with TS born to mothers with gestational hypertension appear to have a higher prevalence of CAs. These findings suggest that maternal gestational hypertension may serve as a potential early clinical marker for increased cardiovascular risk in this population and may warrant closer postnatal cardiac surveillance.
- 11 August 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1576434
Open AccessCardiovascular abnormalities in children with Turner syndrome: a 15-year retrospective study and analysis of warning signs
Background/Objective: There are limited studies on cardiovascular abnormalities (CAs) and their warning signs in children with Turner syndrome (TS). The main aim of this 15-year retrospective study was to investigate the warning signs of CAs in children with TS and to suggest ways to prevent them.Methods: This retrospective study analyzed children diagnosed with TS at our pediatric endocrinology clinic. The study examined patients with TS with CAs and their warning signs.Results: A total of 37 cases were included in our study. The average age at presentation was 7.48 ± 3.49 years. According to the results of transthoracic echocardiography, the children were divided into two groups: (1) TS without CAs (n = 31) and (2) TS with CAs (n = 6). The incidence rate of CAs was 16.2% (6/37). Of the six cases, five had congenital heart disease, four of which underwent cardiac surgery. One patient developed descending aortic coarctation during growth hormone therapy and underwent aortic coarctation repair surgery. The proportions of haplotypes, chimeric types, and structural abnormalities in the TS without CAs group were 9/31, 16/31, and 6/31, respectively. In the TS with CAs group, these proportions were as follows: 1/6, 3/6, and 2/6, respectively. A comparative analysis revealed no statistically significant variation in karyotype frequencies between the two groups. In the TS without CAs group, 0.0% of the mothers had abnormal blood pressure during pregnancy. In the TS with CAs group, the incidence of hypertension in the mothers during pregnancy was 33.3%. A significant difference in gestational hypertension was observed between the two groups (P = 0.016). However, no significant differences were observed between the groups in terms of heart rate or blood pressure parameters (systolic/diastolic).Conclusions: Children with TS born to mothers with gestational hypertension appear to have a higher prevalence of CAs. These findings suggest that maternal gestational hypertension may serve as a potential early clinical marker for increased cardiovascular risk in this population and may warrant closer postnatal cardiac surveillance.
- Open Access
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1518548
Investigation of vitamin D deficiency in girls with growth and development variations—a single center study
Purpose: To understand the status of vitamin D deficiency in girls with growth and developmental variations, as well as the impact of COVID−19 on their vitamin D levels, and to provide reference for the prevention and treatment of vitamin D deficiency in children.Methods: A retrospective analysis was conducted on 1,345 instances of girls with growth and developmental variations who visited our pediatric endocrinology department and completed vitamin D detection. A total of 279 girls with complete data were included in this study. Among them, 246 girls were classified into four groups based on different growth and developmental variations: early puberty group, menarche group, obesity group, short stature group, and 33 healthy girls served as the control group. Besides, the girls were divided into pre-epidemic and post-epidemic groups by the occurrence of the COVID-19 epidemic. Vitamin D were measured in all girls. The 25(OH)D P < 0.05). The individual vitamin D deficiency rates in the aforementioned groups were 52.07%, 73.91%, 59.46%, 30.95%, and 30.30%, respectively. The vitamin D levels in the pre-epidemic and post-epidemic groups were 20.48 ± 6.22 ng/ml and 22.50 ± 9.74 ng/ml, respectively (P > 0.05).Conclusion: Girls with early puberty, menarche, and obesity have a certain deficiency of vitamin D levels, and appropriate vitamin D treatment should be provided clinically. Girls with short stature and healthy girls also have certain levels of vitamin D deficiency, and awareness of prevention should be strengthened.
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1518548
Open AccessInvestigation of vitamin D deficiency in girls with growth and development variations—a single center study
Purpose: To understand the status of vitamin D deficiency in girls with growth and developmental variations, as well as the impact of COVID−19 on their vitamin D levels, and to provide reference for the prevention and treatment of vitamin D deficiency in children.Methods: A retrospective analysis was conducted on 1,345 instances of girls with growth and developmental variations who visited our pediatric endocrinology department and completed vitamin D detection. A total of 279 girls with complete data were included in this study. Among them, 246 girls were classified into four groups based on different growth and developmental variations: early puberty group, menarche group, obesity group, short stature group, and 33 healthy girls served as the control group. Besides, the girls were divided into pre-epidemic and post-epidemic groups by the occurrence of the COVID-19 epidemic. Vitamin D were measured in all girls. The 25(OH)D P < 0.05). The individual vitamin D deficiency rates in the aforementioned groups were 52.07%, 73.91%, 59.46%, 30.95%, and 30.30%, respectively. The vitamin D levels in the pre-epidemic and post-epidemic groups were 20.48 ± 6.22 ng/ml and 22.50 ± 9.74 ng/ml, respectively (P > 0.05).Conclusion: Girls with early puberty, menarche, and obesity have a certain deficiency of vitamin D levels, and appropriate vitamin D treatment should be provided clinically. Girls with short stature and healthy girls also have certain levels of vitamin D deficiency, and awareness of prevention should be strengthened.
- Open Access
- 12 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1458487
Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review
Background: Epilepsy during recombinant human growth hormone (rhGH) therapy is rare in children. The potential association between rhGH treatment and epilepsy remains unclear.Methods: We retrospectively analyzed the clinical data of two Chinese boys who experienced epilepsy during the use of rhGH and reviewed the relevant literature.Results: Case 1, an 8-year and 2-month-old boy, was diagnosed with short stature, malnutrition, and congenital hypothyroidism. He was on levothyroxine sodium tablets for a long time. Recurrent febrile convulsions were present at 6–7 years. Electroencephalogram and magnetic resonance imaging (MRI) showed no abnormality, and no treatment was given. He was diagnosed with complex febrile convulsions. The boy started rhGH treatment (approximately 0.15 IU/kg/day, sc, qd) at 8 years and 4 months. Epilepsy occurred three times during the 6 months of rhGH treatment. Electroencephalography confirmed a definitive diagnosis of epilepsy. Then, he discontinued rhGH treatment at 8 years and 11 months and started taking levetiracetam (0.25 g, po, bid) for antiepileptic therapy. Epilepsy was well-controlled 4 months later. He continued rhGH treatment at 10 years and 3 months and has been on rhGH treatment until now, with no recurrence of epilepsy. He has been taking levetiracetam to date. Case 2, a 9-year and 1-month-old boy, was diagnosed with central precocious puberty, predicted short final height, and overweight. He started treatment with triptorelin (3.75 mg, im, q4w) and rhGH (approximately 0.15 IU/kg/day, sc, qd) at 9 years and 3 months. He tended to fall repeatedly when he was approximately 10 years old. Electroencephalography showed a few medium- to high-amplitude sharp waves and sporadic sharp slow waves in the left middle temporal region, sometimes involving the left posterior temporal region. He was diagnosed with epilepsy. Triptorelin discontinuance provided no symptom relief, which worsened further. Subsequently, he withdrew from rhGH treatment, and the symptoms occurred occasionally within a week and stopped after 15 days. The electroencephalogram returned to normal. No further seizures occurred during follow-up to date.Conclusion: During the use of rhGH in short-stature children with complex febrile convulsions or underlying lesions related to neurological impairment or those being treated with antiepileptic drugs, epilepsy may be induced.
- 12 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1458487
Open AccessCase report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review
Background: Epilepsy during recombinant human growth hormone (rhGH) therapy is rare in children. The potential association between rhGH treatment and epilepsy remains unclear.Methods: We retrospectively analyzed the clinical data of two Chinese boys who experienced epilepsy during the use of rhGH and reviewed the relevant literature.Results: Case 1, an 8-year and 2-month-old boy, was diagnosed with short stature, malnutrition, and congenital hypothyroidism. He was on levothyroxine sodium tablets for a long time. Recurrent febrile convulsions were present at 6–7 years. Electroencephalogram and magnetic resonance imaging (MRI) showed no abnormality, and no treatment was given. He was diagnosed with complex febrile convulsions. The boy started rhGH treatment (approximately 0.15 IU/kg/day, sc, qd) at 8 years and 4 months. Epilepsy occurred three times during the 6 months of rhGH treatment. Electroencephalography confirmed a definitive diagnosis of epilepsy. Then, he discontinued rhGH treatment at 8 years and 11 months and started taking levetiracetam (0.25 g, po, bid) for antiepileptic therapy. Epilepsy was well-controlled 4 months later. He continued rhGH treatment at 10 years and 3 months and has been on rhGH treatment until now, with no recurrence of epilepsy. He has been taking levetiracetam to date. Case 2, a 9-year and 1-month-old boy, was diagnosed with central precocious puberty, predicted short final height, and overweight. He started treatment with triptorelin (3.75 mg, im, q4w) and rhGH (approximately 0.15 IU/kg/day, sc, qd) at 9 years and 3 months. He tended to fall repeatedly when he was approximately 10 years old. Electroencephalography showed a few medium- to high-amplitude sharp waves and sporadic sharp slow waves in the left middle temporal region, sometimes involving the left posterior temporal region. He was diagnosed with epilepsy. Triptorelin discontinuance provided no symptom relief, which worsened further. Subsequently, he withdrew from rhGH treatment, and the symptoms occurred occasionally within a week and stopped after 15 days. The electroencephalogram returned to normal. No further seizures occurred during follow-up to date.Conclusion: During the use of rhGH in short-stature children with complex febrile convulsions or underlying lesions related to neurological impairment or those being treated with antiepileptic drugs, epilepsy may be induced.
- Open Access
- 10 June 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-20
Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive ages. Our previous study has implicated a possible link between RNA editing and PCOS, yet the actual role of RNA editing, its association with clinical features, and the underlying mechanisms remain unclear. Methods: Ten RNA-Seq datasets containing 269 samples of multiple tissue types, including granulosa cells, T helper cells, placenta, oocyte, endometrial stromal cells, endometrium, and adipose tissues, were retrieved from public databases. Peripheral blood samples were collected from twelve PCOS and ten controls and subjected to RNA-Seq. Transcriptome-wide RNA-Seq data analysis was conducted to identify differential RNA editing (DRE) between PCOS and controls. The functional significance of DRE was evaluated by luciferase reporter assays and overexpression in human HEK293T cells. Dehydroepiandrosterone and lipopolysaccharide were used to stimulate human KGN granulosa cells to evaluate gene expression. Results: RNA editing dysregulations across multiple tissues were found to be associated with PCOS in public datasets. Peripheral blood transcriptome analysis revealed 798 DRE events associated with PCOS. Through weighted gene co-expression network analysis, our results revealed a set of hub DRE events in PCOS blood. A DRE event in the eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK2:chr2:37,100,559) was associated with PCOS clinical features such as luteinizing hormone (LH) and the ratio of LH over follicle-stimulating hormone. Luciferase assays, overexpression, and knockout of RNA editing enzyme adenosine deaminase RNA specific (ADAR) showed that the ADAR-mediated editing cis-regulated EIF2AK2 expression. EIAF2AK2 showed a higher expression after dehydroepiandrosterone and lipopolysaccharide stimulation, triggering changes in the downstrean MAPK pathway. Conclusions: Our study presented the first evidence of cross-tissue RNA editing dysregulation in PCOS and its clinical associations. The dysregulation of RNA editing mediated by ADAR and the disrupted target EIF2AK2 may contribute to PCOS development via the MPAK pathway, underlining such epigenetic mechanisms in the disease.
- 10 June 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-20
Open AccessDysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive ages. Our previous study has implicated a possible link between RNA editing and PCOS, yet the actual role of RNA editing, its association with clinical features, and the underlying mechanisms remain unclear. Methods: Ten RNA-Seq datasets containing 269 samples of multiple tissue types, including granulosa cells, T helper cells, placenta, oocyte, endometrial stromal cells, endometrium, and adipose tissues, were retrieved from public databases. Peripheral blood samples were collected from twelve PCOS and ten controls and subjected to RNA-Seq. Transcriptome-wide RNA-Seq data analysis was conducted to identify differential RNA editing (DRE) between PCOS and controls. The functional significance of DRE was evaluated by luciferase reporter assays and overexpression in human HEK293T cells. Dehydroepiandrosterone and lipopolysaccharide were used to stimulate human KGN granulosa cells to evaluate gene expression. Results: RNA editing dysregulations across multiple tissues were found to be associated with PCOS in public datasets. Peripheral blood transcriptome analysis revealed 798 DRE events associated with PCOS. Through weighted gene co-expression network analysis, our results revealed a set of hub DRE events in PCOS blood. A DRE event in the eukaryotic translation initiation factor 2-alpha kinase 2 (EIF2AK2:chr2:37,100,559) was associated with PCOS clinical features such as luteinizing hormone (LH) and the ratio of LH over follicle-stimulating hormone. Luciferase assays, overexpression, and knockout of RNA editing enzyme adenosine deaminase RNA specific (ADAR) showed that the ADAR-mediated editing cis-regulated EIF2AK2 expression. EIAF2AK2 showed a higher expression after dehydroepiandrosterone and lipopolysaccharide stimulation, triggering changes in the downstrean MAPK pathway. Conclusions: Our study presented the first evidence of cross-tissue RNA editing dysregulation in PCOS and its clinical associations. The dysregulation of RNA editing mediated by ADAR and the disrupted target EIF2AK2 may contribute to PCOS development via the MPAK pathway, underlining such epigenetic mechanisms in the disease.
- 29 April 2024
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 132 (07) , 389-395
Diagnostic Value of Stimulated Urine Luteinizing Hormone After Triptorelin Stimulation Test in Girls with Central Precocious Puberty
Objective To investigate the diagnostic value of urine luteinizing hormone (ULH) after the triptorelin stimulation test detected by immunochemiluminometric assay (ICMA) in girls with central precocious puberty (CPP). Methods The girls with precocious puberty were included. The triptorelin stimulation test at 8:30 a.m. was performed. Two consecutive 12-hour urine samples were collected after the test, defined as the first 12-hour and second 12-hour urine, respectively. ICMA measured ULH. Urine creatinine (Cr) concentration was measured. CPP and peripheral precocious puberty (PPP) were diagnosed by the same pediatric endocrinologist based on clinical symptoms, signs, and progression of clinical development. Results A total of 97 cases (CPP n=69; PPP n=28) were included, with 12 cases not meeting the receiver operating characteristic analysis criteria. The first and second 12-hour ULH/Cr in the CPP group were higher than those in the PPP group. When the first 12-hour ULH/Cr was≥287.252 IU/mol, the sensitivity and specificity for diagnosing CPP were 87.3% and 90.9%, respectively. When the second 12-hour ULH/Cr was≥152.769 IU/mol, the sensitivity and specificity for diagnosing CPP were 92.1% and 90.9%, respectively. The area under the curve of the first and second 12-hour ULH/Cr were 0.933 and 0.954, respectively. Conclusion The ULH detection method after the triptorelin stimulation test has clinical significance for diagnosing CPP in girls. When blood sampling compliance in girls with precocious puberty is poor, the first 12-hour ULH/Cr≥288 IU/mol (or second 12-hour≥153 IU/mol) after the triptorelin stimulation test can serve as a laboratory indicator for diagnosis of CPP.
- 29 April 2024
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 132 (07) , 389-395
Diagnostic Value of Stimulated Urine Luteinizing Hormone After Triptorelin Stimulation Test in Girls with Central Precocious Puberty
Objective To investigate the diagnostic value of urine luteinizing hormone (ULH) after the triptorelin stimulation test detected by immunochemiluminometric assay (ICMA) in girls with central precocious puberty (CPP). Methods The girls with precocious puberty were included. The triptorelin stimulation test at 8:30 a.m. was performed. Two consecutive 12-hour urine samples were collected after the test, defined as the first 12-hour and second 12-hour urine, respectively. ICMA measured ULH. Urine creatinine (Cr) concentration was measured. CPP and peripheral precocious puberty (PPP) were diagnosed by the same pediatric endocrinologist based on clinical symptoms, signs, and progression of clinical development. Results A total of 97 cases (CPP n=69; PPP n=28) were included, with 12 cases not meeting the receiver operating characteristic analysis criteria. The first and second 12-hour ULH/Cr in the CPP group were higher than those in the PPP group. When the first 12-hour ULH/Cr was≥287.252 IU/mol, the sensitivity and specificity for diagnosing CPP were 87.3% and 90.9%, respectively. When the second 12-hour ULH/Cr was≥152.769 IU/mol, the sensitivity and specificity for diagnosing CPP were 92.1% and 90.9%, respectively. The area under the curve of the first and second 12-hour ULH/Cr were 0.933 and 0.954, respectively. Conclusion The ULH detection method after the triptorelin stimulation test has clinical significance for diagnosing CPP in girls. When blood sampling compliance in girls with precocious puberty is poor, the first 12-hour ULH/Cr≥288 IU/mol (or second 12-hour≥153 IU/mol) after the triptorelin stimulation test can serve as a laboratory indicator for diagnosis of CPP.
- 23 April 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3323-3333
The Novel Insight of Gut Microbiota from Mouse Model to Clinical Patients and the Role of NF-κB Pathway in Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) is a metabolic disorder characterized by hyperandrogenism and related symptoms in women of reproductive age. Emerging evidence suggests that chronic low-grade inflammation plays a significant role in the development of PCOS. The gut microbiota, a complex bacterial ecosystem, has been extensively studied for various diseases, including PCOS, while the underlying mechanisms are not fully understood. This review comprehensively summarizes the changes in gut microbiota and metabolites observed in PCOS and their potential association with the condition. Additionally, we discuss the role of abnormal nuclear factor κB signaling in the pathogenesis of PCOS. These findings offer valuable insights into the mechanisms of PCOS and may pave the way for the development of control and therapeutic strategies for this condition in clinical practice. By bridging the gap between mouse models and clinical patients, this review contributes to a better understanding of the interplay between gut microbiota and inflammation in PCOS, thus paving new ways for future investigations and interventions.
- 23 April 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (11) , 3323-3333
The Novel Insight of Gut Microbiota from Mouse Model to Clinical Patients and the Role of NF-κB Pathway in Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) is a metabolic disorder characterized by hyperandrogenism and related symptoms in women of reproductive age. Emerging evidence suggests that chronic low-grade inflammation plays a significant role in the development of PCOS. The gut microbiota, a complex bacterial ecosystem, has been extensively studied for various diseases, including PCOS, while the underlying mechanisms are not fully understood. This review comprehensively summarizes the changes in gut microbiota and metabolites observed in PCOS and their potential association with the condition. Additionally, we discuss the role of abnormal nuclear factor κB signaling in the pathogenesis of PCOS. These findings offer valuable insights into the mechanisms of PCOS and may pave the way for the development of control and therapeutic strategies for this condition in clinical practice. By bridging the gap between mouse models and clinical patients, this review contributes to a better understanding of the interplay between gut microbiota and inflammation in PCOS, thus paving new ways for future investigations and interventions.